[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NZ730092A - Use of cysteamine in treating infections caused by yeasts/moulds - Google Patents

Use of cysteamine in treating infections caused by yeasts/moulds

Info

Publication number
NZ730092A
NZ730092A NZ730092A NZ73009215A NZ730092A NZ 730092 A NZ730092 A NZ 730092A NZ 730092 A NZ730092 A NZ 730092A NZ 73009215 A NZ73009215 A NZ 73009215A NZ 730092 A NZ730092 A NZ 730092A
Authority
NZ
New Zealand
Prior art keywords
cysteamine
yeasts
moulds
infections caused
treating infections
Prior art date
Application number
NZ730092A
Inventor
Vanessa Duncan
Deborah O’Neil
Original Assignee
Novabiotics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novabiotics Ltd filed Critical Novabiotics Ltd
Publication of NZ730092A publication Critical patent/NZ730092A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to the use of cysteamine for the manufacture of a medicament for treating or preventing infections caused by yeasts or moulds.
NZ730092A 2014-09-22 2015-09-21 Use of cysteamine in treating infections caused by yeasts/moulds NZ730092A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462053523P 2014-09-22 2014-09-22
GBGB1416727.4A GB201416727D0 (en) 2014-09-22 2014-09-22 Use
PCT/GB2015/052714 WO2016046524A1 (en) 2014-09-22 2015-09-21 Use of cysteamine in treating infections caused by yeasts/moulds

Publications (1)

Publication Number Publication Date
NZ730092A true NZ730092A (en) 2018-05-25

Family

ID=51869299

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ730092A NZ730092A (en) 2014-09-22 2015-09-21 Use of cysteamine in treating infections caused by yeasts/moulds

Country Status (14)

Country Link
EP (1) EP3197476A1 (en)
JP (1) JP2017532317A (en)
KR (1) KR20170052613A (en)
CN (1) CN106687140A (en)
AU (1) AU2015323566B2 (en)
BR (1) BR112017005272A2 (en)
CA (1) CA2959003A1 (en)
GB (1) GB201416727D0 (en)
MX (1) MX2017003550A (en)
NZ (1) NZ730092A (en)
RU (1) RU2017108196A (en)
SG (1) SG11201701648UA (en)
WO (1) WO2016046524A1 (en)
ZA (1) ZA201701330B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2770113T3 (en) 2015-07-02 2020-06-30 Horizon Orphan Llc ADO-resistant cysteamine analogues and their uses
JP2020505359A (en) * 2017-01-25 2020-02-20 アデア ファーマシューティカルズ，インコーポレイテッド Cysteamine prodrug
WO2018224813A1 (en) * 2017-06-06 2018-12-13 Novabiotics Limited Use of cysteamine compositions
CA3116637A1 (en) * 2018-10-17 2020-04-23 Novabiotics Limited Dosage regime
CN110551637B (en) * 2019-09-03 2020-11-27 黑龙江省农业科学院植物保护研究所 Echinospora echinocandii from radix astragali root for efficiently inhibiting botrytis cinerea and application thereof
CN110859950B (en) * 2019-11-25 2021-08-10 武汉大学 Pharmaceutical composition for candida albicans echinocandin drug-resistant bacteria and application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696164A (en) * 1994-12-22 1997-12-09 Johnson & Johnson Consumer Products, Inc. Antifungal treatment of nails
US6086921A (en) * 1995-04-25 2000-07-11 Wintrop-University Hospital Metal/thiol biocides
ES2613027T3 (en) * 2004-08-18 2017-05-22 Novabiotics Limited Antibacterial peptides
JP2006347989A (en) * 2005-06-20 2006-12-28 Pola Chem Ind Inc Antifungal medicine composition for nail
JP2006347990A (en) * 2005-06-20 2006-12-28 Pola Chem Ind Inc Antifungal medicine composition for nail
GB0905451D0 (en) * 2009-03-31 2009-05-13 Novabiotics Ltd Biofilms
MX2012001766A (en) * 2009-08-13 2012-03-07 Moberg Derma Ab Compositions and methods for treating fungal infection of the nail.
GB201021186D0 (en) * 2010-12-14 2011-01-26 Novabiotics Ltd Composition

Also Published As

Publication number Publication date
RU2017108196A3 (en) 2019-06-19
AU2015323566B2 (en) 2018-03-22
WO2016046524A1 (en) 2016-03-31
JP2017532317A (en) 2017-11-02
AU2015323566A1 (en) 2017-04-06
EP3197476A1 (en) 2017-08-02
RU2017108196A (en) 2018-10-24
ZA201701330B (en) 2018-04-25
KR20170052613A (en) 2017-05-12
CN106687140A (en) 2017-05-17
MX2017003550A (en) 2017-07-28
BR112017005272A2 (en) 2017-12-12
SG11201701648UA (en) 2017-04-27
CA2959003A1 (en) 2016-03-31
GB201416727D0 (en) 2014-11-05

Similar Documents

Publication Publication Date Title
IL283086A (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
IL279627A (en) Method for the treatment of depression
PH12016501763A1 (en) Multispecific antibodies
SG11201705093UA (en) Composition for treating il-6-related diseases
EA201791110A1 (en) SUBLINGUAL INTRODUCTION OF RHYNESOL
NZ730092A (en) Use of cysteamine in treating infections caused by yeasts/moulds
BR112018003526A2 (en) methods of treating inflammatory diseases
MX2017007188A (en) Antimycotic compound.
PL3145511T3 (en) Composition for treating the eye
EP3169405A4 (en) Methods, compounds, and compositions for the treatment of musculoskeletal diseases
EP3099304A4 (en) Novel therapeutics for the treatment of glaucoma
EP3200749A4 (en) Methods for the treatment of peri-implantitis
EP3136840A4 (en) Aided delivery of plant treatment agents
MX2016012758A (en) Hyperosmolar composition of hyaluronic acid.
EP3183270A4 (en) Hiv antibody therapy as treatment substitute
SG10201903630UA (en) Iminosugars useful for the treatment of viral diseases
GB2571647B (en) The use of dipropylene/diethylene glycol dibenzoate to reduce eye irritation
IN2014CH01391A (en)
HUP1400518A2 (en) Process for the preparation of tofacitinib
IL251040A0 (en) Use of cysteamine in treating infections caused by yeasts/moulds
PH12018500339A1 (en) Lysobactin for use in the treatment of bovine mastitis
GB201521802D0 (en) Mould treatment
PH12014000104A1 (en) Therapeutic methods and compositions for treating diabetes
GB201410990D0 (en) General cure to diseases
IN2014CH00872A (en)

Legal Events

Date Code Title Description
PSEA Patent sealed
LAPS Patent lapsed